Trials / Recruiting
RecruitingNCT06819215
Phase I/II Clinical Study to Evaluate VB15010 Tablets in Patients With Advanced Solid Tumors
Phase I/II Clinical Study To Evaluate The Safety, Tolerability, Pharmacokinetics, Pharmacodynamics And Preliminary Efficacy of VB15010 Tablets In Patients With Advanced Solid Tumors
- Status
- Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 188 (estimated)
- Sponsor
- Zhejiang Yangli Pharmaceutical Technology Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This research is designed to determine if experimental treatment with PARP1 inhibitor, VB15010 is safe, tolerable, and has anti-cancer activity in patients with advanced solid tumors.
Conditions
- Cancer
- Neoplasms
- Neoplasms, Breast
- Tumor
- PARP
- Ovarian Neoplasms
- Prostatic Cancer
- Pancreatic Cancer
- Breast Cancer
- Biliary Cancer
- Colorectal Cancer
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | VB15010 | Oral PARP1 inhibitor |
Timeline
- Start date
- 2024-10-30
- Primary completion
- 2025-12-30
- Completion
- 2026-03-30
- First posted
- 2025-02-11
- Last updated
- 2025-02-11
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06819215. Inclusion in this directory is not an endorsement.